Xin Lang Cai Jing·2025-10-22 09:35Core Viewpoint - The company Haiprui is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms. Its main business includes the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company’s revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.564 billion yuan [1]. Market Position - The company has a significant overseas revenue share of 93.04%, which is positively impacted by the depreciation of the RMB [3]. - The stock has shown a recent trading volume of 46.8377 million yuan with a turnover rate of 0.31% [1]. Shareholder Information - As of June 30, 2025, Haiprui had 26,300 shareholders, a decrease of 7.29% from the previous period [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares [9]. Dividend History - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].